

## **GRIFOLS, S.A.**

### **PROFESSIONAL PROFILE AND BIOGRAPHY OF THE BOARD MEMBERS WHOSE APPOINTMENTS, RATIFICATIONS OF APPOINTMENTS AND RE-ELECTIONS ARE PROPOSED TO THE ORDINARY GENERAL SHAREHOLDERS' MEETING (13/14 JUNE 2024)**

---

- **Mr. José Ignacio Abia Buenache**

Category: executive.

Before joining Grifols, Mr. José Ignacio Abia Buenache held the position of President and Chief Executive Officer of Olympus Corporation of the Americas based in Pennsylvania (United States) for the last 10 years. Concurrently he has also served as Executive Officer and Chief Operating Officer (COO) and Chief Strategy Officer (CSO) at Olympus Corporation, a publicly traded company in the Tokyo stock exchange.

Mr. José Ignacio Abia has accumulated more than two decades of experience in Medical technology and Life Sciences industries, with half of that time spent in the United States and the other half in Europe. At Olympus he also dedicated a significant amount of time to developing the business in the Asia-Pacific region. Prior to joining Olympus, he held several positions in the IT and Consumer Electronics industries working for a variety of technology companies, including Sony and Techdata.

In the academic field, Mr. José Ignacio Abia holds a Bachelor's Degree in Telecommunications and Electronics Engineering from the Universitat Politècnica de Catalunya (UPC), he holds a Master of Business Administration (MBA) from the business school (EAE) of Barcelona, and has completed the Senior Management Program (PADE) at IESE (University of Navarra).

Mr. José Ignacio Abia also serves in the Board of Directors of the US-Spain Chamber of Commerce and is a member of the Board of Trustees of the Lehigh Valley Health Network, a hospital system composed of 13 hospitals and multiple care centres in Pennsylvania. In the past, he was member of the Board of Directors of Evident Corporation, a company in the field of life sciences and industrial solutions.

▪ **Mr. Albert Grifols Coma-Cros**

Category: proprietary.

Mr. Albert Grifols Coma-Cros joined the Grifols Group in 2004 as an Analyst in the Planning and Control Department. During 2007 he moved to the Finance Department as a Financial Analyst. In 2013 he held the position of Corporate Treasury Director and moved to Ireland to develop and implement the Group's global financial structure. From 2018 to 2020 he was appointed Managing Director of Grifols Worldwide Operations Ltd. in Ireland, being responsible for supervising the correct functioning of Grifols in Ireland, ensuring the correct collusion between Irish culture and Grifols' own values in the gradual growth of the subsidiary in the country. Since 2021 and until 2023 he has served as Chief Scientific Innovation Officer, being responsible for bringing together all the Group's scientific knowledge previously dispersed under a single scientific organization.

Academically, Mr. Albert Grifols Coma-Cros holds a degree in Business Administration from the Universitat Autònoma de Barcelona and has completed several Management Development Programs at ESADE, Georgetown University or the Institut Estudis Financers (IEF).

Furthermore, since 2015 he has also been a director of the Board of Directors of Fisa 14, S.A., a real estate company and President of Bansabadell 18, FP, a pension fund since 2018.

▪ **Mrs. Claire Giraut**

Category: independent.

Mrs. Claire Giraut brings to Grifols her extensive executive and non-executive experience in the corporate and financial world, in leading international companies in the healthcare and other industrial sectors.

Since 2022, Mrs. Claire Giraut has been a member of the Board of Directors and Chair of the Audit Committee of Euroapi, a company specializing in active ingredient solutions for the pharmaceutical industry, based in Paris. In addition, since 2021, she chairs the Financial Committee of the Institut Curie, a recognized cancer research and treatment center in Paris. Previously, from 2010 to 2022 she was a member of the Board of Directors and of the Audit Committee of Julius Baer, a leader in private banking based in Zurich, and from 2020 to 2022 the Chair of its Development and Innovation Committee. In addition, from 2016 to 2021, Mrs. Claire Giraut was a member of the Board of Directors and Chair of the Audit Committee of DBV Technologies, a clinical-stage biotechnology company. Before that, from 2010 to 2016, she was a member of the Board of Directors and of the Audit Committee of Heurtey Petrochem, an engineering and construction company based in Paris.

In terms of executive experience, Mrs. Claire Giraut has held senior financial roles in internationally renowned companies. From 2013 to 2018, she was the Executive Vice President and Chief Financial Officer of BioMérieux, a global in-vitro diagnostics company. Prior to joining BioMérieux, in 2011-2012 she was Chief Financial Officer of Europcar Group in Paris, and from 2003 to 2011 she was Executive Vice President and Chief Financial Officer of IPSEN, a pharmaceutical company based in Paris. She also held senior positions at Technip, a leading engineering company based in Paris, and at Coflexip Stena Offshore, a subsea oil and gas engineering and construction company.

On the academic side, Mrs. Claire Giraut holds a Master's degree in Agronomy from the Institut National Agronomique de Paris, now known as AgroParisTech.

▪ **Mrs. Anne – Catherine Berner**

Category: independent.

Mrs. Anne-Catherine Berner brings to Grifols her extensive executive and non-executive experience in the financial, healthcare and other industrial sectors. Her professional journey encompasses leadership roles in various publicly listed and privately held international companies and organizations across multiple sectors, highlighting the financial sector.

Mrs. Berner's career is deeply rooted in Vallila Interior AB, a family-owned interior design company. She joined the company in 1986 and became Chief Executive Officer and Chairwoman of the Board in 1989, steering its growth until 2012.

Besides her career as an executive business professional, she served as a Member of the Finnish Parliament and as Minister for Transport and Communications from 2015 to 2019, within the Finnish government. Simultaneously, she maintained presence in the international business arena, contributing her expertise as a board member and Chairwoman in several industries, such as forestry and paper, insurance, and building materials.

Currently, Mrs. Berner holds Board roles in several entities. She serves as a board member of Kühne + Nagel AG, a global transport and logistics company, and SEB AB, a public Nordic financial services group. Since 2022, she has chaired the Advisory Board of Getec Energie Holding GmbH in Germany, a notable player in energy services. Additionally, she joined the Board of Medicover AB in 2022, focusing on healthcare and diagnostic services primarily in Central and Eastern Europe. Also, she is currently the Chairwoman of the Board of the Foundation for Children's trauma hospital and institution Nadija sr, in Helsinki.

On the academic side, Mrs. Anne-Catherine Berner holds a Master of Science Degree in Business Administration and Economics, from the Hanken School of Economics, Helsinki, Finland.

\* \* \*